Hillsborough, NJ, United States of America

Sesha Iyer Natarajan

USPTO Granted Patents = 2 

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 34(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Sesha Iyer Natarajan: Innovator in Diabetes Treatment

Introduction

Sesha Iyer Natarajan is a notable inventor based in Hillsborough, NJ (US). He has made significant contributions to the field of diabetes treatment through his innovative research and development of peptide mimics.

Latest Patents

Natarajan holds 2 patents related to human glucagon-like-peptide-1 (GLP-1) mimics. His latest patents focus on the development of novel GLP-1 peptide mimics that replicate the biological activity of the native GLP-1 peptide. These innovations are aimed at treating or preventing diseases associated with GLP activity. The chemically modified peptides not only stimulate insulin secretion in type II diabetics but also produce other beneficial insulinotropic responses. Furthermore, these synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage, making them ideal candidates for oral or parenteral administration.

Career Highlights

Natarajan is currently associated with Bristol-Myers Squibb Company, where he continues to advance his research in diabetes treatment. His work has been instrumental in developing therapeutic solutions that enhance the quality of life for individuals with diabetes.

Collaborations

Some of his notable coworkers include Claudio Mapelli and Margarita Bastos, who contribute to the collaborative efforts in research and development within the company.

Conclusion

Sesha Iyer Natarajan's innovative work in the field of diabetes treatment through his patented peptide mimics showcases his dedication to improving healthcare solutions. His contributions are paving the way for more effective treatments for diabetes and related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…